OBJECTIVES: The aim of this study was to classify and quantify the high fluorescence lymphocytes area (HFL-count) from the SYSMEX XE-2100 leucocyte differential channel as antibody-synthesizing or -secreting cells (ASC, plasma cells or lymphoplasmacytoid cells) in reactive diseases. To unequivocally identify the HFL cells, all possibly eligible cell populations have been investigated: activated B-lymphocytes, activated T-lymphocytes, large granular lymphocytes (LGL), activated monocytes, and immature granulocytes. METHODS: In total, 85 patients were analyzed on the XE-2100 and compared with the automated image analysis system Cellavision Diffmaster 96 based on artificial neural network and immunophenotyping method with the BD FACSCalibur. RESULTS: Reproducibility tests for HFL demonstrated a mean coefficient of variation of 13.9% for very low results and 1.5% for high results. The linearity data showed a good correlation (R(2) = 0.99) between expected and measured HFL. The comparison with possibly eligible cell populations showed no significant correlation between activated monocytes and immature granulocytes, with most immature granulocytes (promyelocyte I or II), natural killer cells or LGLs, activated T-lymphocytes, and sub-T-lymphocytes populations. However, for activated B-lymphocytes an excellent significant correlation with the peripheral blood smear, and the immunophenotyping method has been found with R(2) = 0.900, P < 0.001 and R(2) = 0.897, P < 0.001, respectively. The slope of 1.1 and intercept of minus 5 cells/microL of the regression equation between HFL-count and ASC (smear) do indicate an excellent quantification of the HFL-count, as well. CONCLUSION: The fully automated SYSMEX XE-2100 HFL-count identifies and quantifies the ASC cells (activated B-lymphocytes) with high precision and reliability in patients without hematology system diseases, thus providing a potential screening and monitoring tool for any patient with suspected infection. Additional studies are required to comprehend in more detail the full clinical utility of an HFL (ASC) count as a potential diagnostic indicator of inflammation, infection, or sepsis. Copyright 2007 Clinical Cytometry Society.
OBJECTIVES: The aim of this study was to classify and quantify the high fluorescence lymphocytes area (HFL-count) from the SYSMEX XE-2100 leucocyte differential channel as antibody-synthesizing or -secreting cells (ASC, plasma cells or lymphoplasmacytoid cells) in reactive diseases. To unequivocally identify the HFL cells, all possibly eligible cell populations have been investigated: activated B-lymphocytes, activated T-lymphocytes, large granular lymphocytes (LGL), activated monocytes, and immature granulocytes. METHODS: In total, 85 patients were analyzed on the XE-2100 and compared with the automated image analysis system Cellavision Diffmaster 96 based on artificial neural network and immunophenotyping method with the BD FACSCalibur. RESULTS: Reproducibility tests for HFL demonstrated a mean coefficient of variation of 13.9% for very low results and 1.5% for high results. The linearity data showed a good correlation (R(2) = 0.99) between expected and measured HFL. The comparison with possibly eligible cell populations showed no significant correlation between activated monocytes and immature granulocytes, with most immature granulocytes (promyelocyte I or II), natural killer cells or LGLs, activated T-lymphocytes, and sub-T-lymphocytes populations. However, for activated B-lymphocytes an excellent significant correlation with the peripheral blood smear, and the immunophenotyping method has been found with R(2) = 0.900, P < 0.001 and R(2) = 0.897, P < 0.001, respectively. The slope of 1.1 and intercept of minus 5 cells/microL of the regression equation between HFL-count and ASC (smear) do indicate an excellent quantification of the HFL-count, as well. CONCLUSION: The fully automated SYSMEX XE-2100 HFL-count identifies and quantifies the ASC cells (activated B-lymphocytes) with high precision and reliability in patients without hematology system diseases, thus providing a potential screening and monitoring tool for any patient with suspected infection. Additional studies are required to comprehend in more detail the full clinical utility of an HFL (ASC) count as a potential diagnostic indicator of inflammation, infection, or sepsis. Copyright 2007 Clinical Cytometry Society.
Authors: Patrick J van der Geest; Mostafa Mohseni; Jo Linssen; Servet Duran; Robert de Jonge; A B Johan Groeneveld Journal: Crit Care Date: 2016-07-07 Impact factor: 9.097
Authors: Christina Y C Yip; Eng Soo Yap; Sanjay De Mel; Winnie Z Y Teo; Chun-Tsu Lee; Sheryl Kan; Melvin C C Lee; Will N H Loh; Er Luen Lim; Shir Ying Lee Journal: Br J Haematol Date: 2020-06-02 Impact factor: 6.998
Authors: Annelies Post; Berenger Kaboré; Joel Bognini; Salou Diallo; Palpouguini Lompo; Basile Kam; Natacha Herssens; Fred van Opzeeland; Christa E van der Gaast-de Jongh; Jeroen D Langereis; Marien I de Jonge; Janette Rahamat-Langendoen; Teun Bousema; Heiman Wertheim; Robert W Sauerwein; Halidou Tinto; Jan Jacobs; Quirijn de Mast; Andre J van der Ven Journal: PLoS Negl Trop Dis Date: 2021-03-01
Authors: Mary Boulanger; Emily Molina; Kunbo Wang; Thomas Kickler; Yanxun Xu; Brian T Garibaldi Journal: Am J Med Date: 2021-03-31 Impact factor: 4.965
Authors: Joachim Linssen; Anthony Ermens; Marvin Berrevoets; Michela Seghezzi; Giulia Previtali; Simone van der Sar-van der Brugge; Henk Russcher; Annelies Verbon; Judith Gillis; Jürgen Riedl; Eva de Jongh; Jarob Saker; Marion Münster; Imke Ca Munnix; Anthonius Dofferhof; Volkher Scharnhorst; Heidi Ammerlaan; Kathleen Deiteren; Stephan Jl Bakker; Lucas Joost Van Pelt; Yvette Kluiters-de Hingh; Mathie Pg Leers; Andre J van der Ven Journal: Elife Date: 2020-11-26 Impact factor: 8.140